QIAGEN and Idaho Technology Settle Patent Dispute

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




Patents in this agreement  targeting rapid polymerase chain  reaction
and High Resolution Melting on Corbett's Rotor-Gene instruments

Venlo, The  Netherlands and  Salt Lake  City, UT,  August 4,  2008  -
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) and  Idaho
Technology, Inc.  are pleased  to announce  that the  companies  have
reached a settlement agreement for rights to a suite of  intellectual
property  relating  to  Corbett's  Rotor-Gene(TM)  instruments.  This
settlement preceded QIAGEN's acquisition of Corbett Life Science Pty.
Ltd. announced on July 1, 2008. The financial terms of the  agreement
were not disclosed.

The agreement covers Idaho Technology, Inc. patents surrounding rapid
polymerase chain  reaction methods  and instrumentation,  the use  of
SYBR® Green  I  in  PCR reactions,  melting  curve  analysis  (rights
obtained through  Roche Diagnostics  GmbH), analysis  methods of  DNA
melting data, specifically high resolution melting (HRM), and others.

The parties further agreed to jointly file a stipulation of dismissal
with prejudice with the District Court  in Salt Lake City to end  the
pending legal proceedings.

This settlement follows  Idaho Technology's  January 2007  settlement
with Cepheid  involving  similar intellectual  property  and  extends
Idaho Technology's program  to protect  their broad  and valuable  IP
portfolio.

"We are pleased with  this settlement which was  a condition for  our
transaction with  Corbett and  which  provides customers  of  Corbett
cyclers and QIAGEN the  key freedom to  operate elements required  to
develop,  market  and  operate  performance  leading  real-time   PCR
detection  technologies  based  on  Corbett's  innovative  Rotor-Gene
solutions", said Peer Schatz, QIAGEN's Chief Executive Officer.

"Idaho Technology is a company built on innovation; we are pleased to
have reached a settlement with QIAGEN/Corbett and we look forward  to
working  with  QIAGEN.  Protecting  our  intellectual  property  will
continue to be  exceedingly important  to our  business." said  Randy
Rasmussen, President, Idaho Technology, Inc.

About QIAGEN
QIAGEN N.V., a Netherlands holding  company, is the leading  provider
of sample and  assay technologies.  Sample technologies  are used  to
isolate and process  DNA, RNA, and  proteins from biological  samples
such as blood  or tissue. Assay  technologies are used  to make  such
isolated biomolecules visible. QIAGEN has developed and markets  more
than 500 consumable products as well as automated solutions for  such
consumables.  The  company   provides  its   products  to   molecular
diagnostics laboratories,  academic researchers,  pharmaceutical  and
biotechnology companies, and applied  testing customers for  purposes
such as forensics, animal or food testing, and pharmaceutical process
control. QIAGEN's assay technologies include what is considered to be
the broadest panel of molecular diagnostic tests available worldwide.
This  panel   includes  the   only   FDA-approved  test   for   human
papillomavirus (HPV), the  primary cause of  cervical cancer.  QIAGEN
employs more than 2,700 people  in more than 30 locations  worldwide.
Further information about QIAGEN can be found at www.qiagen.com.

About Idaho Technology, Inc.
Idaho Technology,  Inc. is  a  privately held  biotechnology  company
based in  Salt Lake  City, Utah.  Founded in  1990, Idaho  Technology
licensed the  rapid  PCR  technology from  the  University  of  Utah.
Through funds from the United  States Department of Health and  Human
Services and the Department of Defense, the company has created  many
commercial instruments and reagents for  use in research and  applied
fields.  Several  of  these  products,  including  the   LightCycler®
Instrument, have been sublicensed to Roche Diagnostics.  Researchers,
medical technicians, law  enforcement officers, and  soldiers in  the
field use the  company's devices to  detect or study  disease-causing
organisms. For further information, please visit www.idahotech.com.

Certain of  the statements  contained  in this  news release  may  be
considered forward-looking statements within  the meaning of  Section
27A of the U.S. Securities Act  of 1933, as amended, and Section  21E
of the  U.S. Securities  Exchange Act  of 1934,  as amended.  To  the
extent that  any  of  the statements  contained  herein  relating  to
QIAGEN's  products,  markets,  strategy  or  operating  results   are
forward-looking, such statements  are based  on current  expectations
that involve a number of uncertainties and risks. Such  uncertainties
and risks  include, but  are not  limited to,  risks associated  with
management of  growth  and international  operations  (including  the
effects  of  currency  fluctuations   and  risks  of  dependency   on
logistics),  variability   of  operating   results,  the   commercial
development of the applied testing markets, clinical research markets
and proteomics  markets,  nucleic  acid-based  molecular  diagnostics
market,  and   genetic   vaccination  and   gene   therapy   markets,
competition,   rapid   or   unexpected   changes   in   technologies,
fluctuations in demand for QIAGEN's, products (including fluctuations
due to the level and timing of customers' funding, budgets, and other
factors), our ability to obtain regulatory approval of our infectious
disease  panels,  difficulties  in  successfully  adapting   QIAGEN's
products to  integrated solutions  and producing  such products,  the
ability of  QIAGEN  to  identify  and develop  new  products  and  to
differentiate  its  products   from  competitors'  products,   market
acceptance of QIAGEN's new products  and the integration of  acquired
technologies and businesses.  For further information,  refer to  the
discussions in reports that QIAGEN  has filed with, or furnished  to,
the U.S. Securities and Exchange Commission (SEC).


Contacts:


Dr. Solveigh Mähler                Dr. Thomas Theuringer
Director Investor Relations        Associate     Director      Public
QIAGEN N.V.                        Relations
[phone]                  QIAGEN GmbH
e-mail:                            [phone]
[e-mail]        email:
                                   [e-mail]

Albert F. Fleury                   For Idaho:
Investor Relations North America   Randy Rasmussen
QIAGEN N.V.                        President
[phone]                    Idaho Technology, Inc
e-mail: [e-mail]   [phone]
                                   e-mail: [e-mail]


 
--- End of Message ---

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands

WKN: 901626; ISIN: 
NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, 
TecDAX;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in 
Börse Berlin, 
Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische 
Wertpapierbörse zu Hamburg, 
Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in 
Bayerische Börse München, 
Freiverkehr in Börse Stuttgart;